Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (9)
Type
(
1 selected
)
Type
Guidance (412)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (325)
Apply filters
Showing 201 to 250 of 412
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]
Technology appraisal guidance
30 April 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Technology appraisal guidance
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Technology appraisal guidance
TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
Technology appraisal guidance
TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]
Technology appraisal guidance
TBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)
NICE guideline
TBC
Managing common infections - antimicrobial prescribing guidelines
NICE guideline
TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
Technology appraisal guidance
TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
Technology appraisal guidance
TBC
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]
Technology appraisal guidance
TBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]
Technology appraisal guidance
26 February 2025
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257
Technology appraisal guidance
TBC
Maternal and child nutrition
NICE guideline
15 January 2025
Melanoma (metastatic) - talimogene laherparepvec [ID508]
Technology appraisal guidance
28 September 2016
Menopause: diagnosis and management
NICE guideline
7 November 2024
Mental health guidelines
NICE guideline
TBC
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]
Technology appraisal guidance
TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
Technology appraisal guidance
TBC
Molnupiravir for treating COVID 19 [ID6340]
Technology appraisal guidance
29 January 2025
MRI-guided focused ultrasound subthalamotomy for treating Parkinson's
Interventional procedures guidance
12 December 2024
MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's
Interventional procedures guidance
12 December 2024
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
Technology appraisal guidance
TBC
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]
Technology appraisal guidance
16 July 2025
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Technology appraisal guidance
TBC
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221
Technology appraisal guidance
21 May 2025
Nemolizumab for treating prurigo nodularis [ID6451]
Technology appraisal guidance
21 May 2025
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
Technology appraisal guidance
28 June 2017
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Technology appraisal guidance
TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Technology appraisal guidance
TBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Technology appraisal guidance
17 July 2024
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Technology appraisal guidance
TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Technology appraisal guidance
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Technology appraisal guidance
TBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Technology appraisal guidance
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
Technology appraisal guidance
TBC
Non-invasive skin closure devices for surgical incisions (MT775)
Medical technologies guidance
TBC
Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome
Diagnostics guidance
19 December 2024
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
Technology appraisal guidance
TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
Technology appraisal guidance
TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]
Technology appraisal guidance
25 June 2025
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Technology appraisal guidance
TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
Technology appraisal guidance
TBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]
Technology appraisal guidance
TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]
Technology appraisal guidance
TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]
Technology appraisal guidance
TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Highly specialised technology
TBC
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423
Technology appraisal guidance
13 August 2025
Previous page
1
…
3
4
Current page
5
6
7
…
9
Page
5
of
9
Next page
Results per page
10
25
50
All
Back to top